{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T21:10:34Z","timestamp":1794258634576,"version":"4.9.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC), but its efficacy varies due to patient heterogeneity. Combining TACE with systemic therapies, such as targeted agents or immune checkpoint inhibitors, has shown promise in improving outcomes, though controversies regarding survival benefits and safety persist. This study investigates whether synchronized systemic therapy enhances the therapeutic efficacy of TACE in intermediate and advanced-stage HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, retrospective study included 142 patients with intermediate and advanced-stage HCC (BCLC B or C) who received TACE as initial treatment between February 2019 and August 2022 at Hunan Provincial People\u2019s Hospital. Patients were divided into two groups: combination therapy (TACE plus systemic therapy, n=41) and TACE monotherapy (n=101). Progression-free survival (PFS), overall survival (OS), treatment response (per mRECIST criteria), and adverse events (AEs) were compared. Cox regression and Kaplan-Meier analyses were used to assess survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No significant differences were observed in baseline characteristics, except for a higher proportion of Child-Pugh A patients in the combination group (90.2% vs. 67.3%, P=\u00a00.005). Median PFS was similar between the combination and monotherapy groups (5.5 vs. 6.0 months, P=\u00a00.832), with no significant differences in BCLC-B (18.3 vs. 17.4 months, P=\u00a00.516) or BCLC-C (4.1 vs. 3.7 months, P=\u00a00.255) subgroups. However, the combination group showed a trend toward improved OS (24.8 vs. 16.7 months, P=\u00a00.282), with a significant benefit in BCLC-C patients (17.9 vs. 11.0 months, P=\u00a00.048). Grade 3 or 4 AEs were comparable between groups (7.2% vs. 14.9%, P=\u00a00.187).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Combining systemic therapy with TACE does not improve PFS but may enhance OS in BCLC-C patients. The safety profile is comparable, particularly in patients with preserved liver function. These findings highlight the importance of patient selection and warrant further prospective studies to optimize treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1819885","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:37:41Z","timestamp":1777613861000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment for intermediate and advanced-stage hepatocellular carcinoma: does systemic therapy synergize the therapeutic efficacy of TACE?"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhuo","family":"Li","sequence":"first","affiliation":[{"name":"Department of Interventional Vascular Surgery, Hunan Provincial People\u2019s Hospital (The First Affiliated Hospital of Hunan Normal University)","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Interventional Vascular Surgery, Hunan Provincial People\u2019s Hospital (The First Affiliated Hospital of Hunan Normal University)","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Interventional Vascular Surgery, Hunan Provincial People\u2019s Hospital (The First Affiliated Hospital of Hunan Normal University)","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Interventional Vascular Surgery, Hunan Provincial People\u2019s Hospital (The First Affiliated Hospital of Hunan Normal University)","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Interventional Vascular Surgery, Hunan Provincial People\u2019s Hospital (The First Affiliated Hospital of Hunan Normal University)","place":["Changsha, China"]},{"name":"Department of Interventional Vascular Surgery, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","article-title":"Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)","volume":"8","author":"Zhu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-09754-2","article-title":"Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study","volume":"33","author":"Jin","year":"2023","journal-title":"Eur Radiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000531377","article-title":"A phase 2, prospective, multicenter, single-arm trial of transarterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable intermediate-stage hepatocellular carcinoma: TACTICS-L trial","volume":"13","author":"Kudo","year":"2023","journal-title":"Liver Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial","volume":"64","author":"Lencioni","year":"2016","journal-title":"J Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolization in patients with unresectable hepatocellular carcinoma (TACE 2): a randomized placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"Meyer","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-074245","article-title":"Cost-effectiveness analysis of adding transarterial chemoembolization to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China","volume":"13","author":"Li","year":"2023","journal-title":"BMJ Open"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2018181494","article-title":"Liver Imaging Reporting and Data System (LI-RADS) Version 2018: imaging of hepatocellular carcinoma in at-risk patients","volume":"289","author":"Chernyak","year":"2018","journal-title":"Radiology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.170.3.2536946","article-title":"Transcatheter oily chemoembolization of hepatocellular carcinoma","volume":"170","author":"Nakamura","year":"1989","journal-title":"Radiology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246370","article-title":"Efficacy of superselective conventional transarterial chemoembolization using guidance software for hepatocellular carcinoma within three lesions smaller than 3 cm","volume":"13","author":"Miyayama","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2015.12.752","article-title":"Transcatheter therapy for hepatic Malignancy: standardization of terminology and reporting criteria","volume":"27","author":"Gaba","year":"2016","journal-title":"J Vasc Interv Radiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-021-03305-3","article-title":"Combined transarterial iodized oil injection and computed tomography-guided thermal ablation for hepatocellular carcinoma: utility of the iodized oil retention pattern","volume":"47","author":"Tan","year":"2022","journal-title":"Abdom Radiol (NY)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2019.05.021","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1543903","article-title":"The efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma: is the alteration of the inflammation index important","volume":"12","author":"Luo","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling survival data: extending the cox model","author":"Therneau","year":"2000"},{"key":"B18","unstructured":"Kassambara\n              A\n            \n            \n              Kosinski\n              M\n            \n            \n              Biecek\n              P\n            \n          \n          survminer: Drawing Survival Curves using 'ggplot2'. R package version 0.4.9\n          \n          2021"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1329906","article-title":"Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions","volume":"32","author":"Bolondi","year":"2012","journal-title":"Semin Liver Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1016\/j.jvir.2020.04.017","article-title":"Clinical significance of the initial and best responses after chemoembolization in the treatment of intermediate-stage hepatocellular carcinoma with preserved liver function","volume":"31","author":"Park","year":"2020","journal-title":"J Vasc Interv Radiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-024-02075-w","article-title":"Hepatocellular carcinoma: signaling pathways and therapeutic advances","volume":"10","author":"Zheng","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1055\/s-0044-1779713","article-title":"Hepatocellular carcinoma: advances in systemic therapy","volume":"41","author":"Selene","year":"2024","journal-title":"Semin Intervent Radiol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1159\/000539897","article-title":"Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and\/or contralateral portal vein invasion in IMbrave150","volume":"13","author":"Finn","year":"2024","journal-title":"Liver Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1739817","article-title":"Neoadjuvant TACE combined with chemo-immunotherapy for giant triple-negative breast cancer: a case report","volume":"17","author":"Tan","year":"2026","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13040950","article-title":"Immunogenic cell death and metabolic reprogramming in cancer: mechanisms, synergies, and innovative therapeutic strategies","volume":"13","author":"Jiang","year":"2025","journal-title":"Biomedicines"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2024.2442573","article-title":"The assessment of impaired liver function and prognosis in hepatocellular carcinoma","volume":"18","author":"Pantea","year":"2024","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70633","article-title":"Transarterial chemoembolization with or without systemic therapy for unresectable hepatocellular carcinoma: a retrospective comparative study","volume":"14","author":"Guo","year":"2025","journal-title":"Cancer Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"100815","DOI":"10.1016\/j.bj.2024.100815","article-title":"Hepatocellular carcinoma systemic treatment update: from early to advanced stage","volume":"48","author":"Teng","year":"2024","journal-title":"BioMed J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111863","article-title":"Platelet-to-lymphocyte ratio predicts tumor response and survival of patients with hepatocellular carcinoma undergoing immunotherapies","volume":"131","author":"Wang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1219694","article-title":"Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma","volume":"14","author":"He","year":"2023","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1819885\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:37:42Z","timestamp":1777613862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1819885\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2026.1819885"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1819885","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"article-number":"1819885"}}